Journal
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
Volume 27, Issue 8, Pages 1300-1308Publisher
SPRINGER JAPAN KK
DOI: 10.1007/s10147-022-02179-9
Keywords
Regorafenib; Dose-escalation; Colorectal cancer; Japanese patients
Categories
Funding
- Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School
Ask authors/readers for more resources
The study demonstrated that dose-escalation therapy of regorafenib is well tolerated for Japanese patients, with improved survival rates and low incidence of adverse events.
Background Regorafenib significantly improves overall survival in previously treated metastatic colorectal cancer patients. However, various toxicities, such as hand-foot skin reaction (HFSR), fatigue, and liver dysfunction have limited the use of regorafenib. These toxicities appear soon after treatment initiation. The ReDOS study demonstrated the effectiveness of a weekly dose-escalation therapy of regorafenib starting with a lower daily dose; however, its usefulness in Asian subjects is unknown. We conducted a phase II study to evaluate the safety and survival benefit of regorafenib dose-escalation therapy for Japanese patients. Methods Patients with sufficient organ function, who had previously received more than two lines of chemotherapy were included. Regorafenib was started at 80 mg/day and escalated to 120 mg/day in Week 2 and 160 mg/day in Week 3, if no severe drug-related toxicities were observed. The primary endpoint was cancer progression-free survival (PFS). Tumor response and progression were assessed radiologically every 8 weeks. This study was registered in the University Hospital Medical Information Network (UMIN#UMIN000028933). Results 57 patients were enrolled and all started regorafenib at 80 mg/day. 32 patients (56.1%) were subsequently escalated to 120 mg/day and 19 (33.3%) to 160 mg/day. Only 8 patients (14.0%) discontinued treatment because of adverse events. Median PFS was 1.9 months. Median overall survival was 8.9 months, the response rate was 0%, and the disease control rate was 31.6%. The most frequent adverse event greater than grade 3 was hypertension (19.3%), followed by HFSR (14.0%). Conclusions Regorafenib dose-escalation therapy is well tolerated with PFS-like regorafenib standard therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available